FDA Lifts Hold on Geron Stem Cell Trial, Shares Leap
WASHINGTON – The FDA's blessing Friday of the world's first clinical trial of a human embryonic stem cell (hESC) therapy has not only launched what may be "the dawn of a new era" for medical treatment, but if successful, the therapies could alleviate much of the burdensome costs plaguing the nation's health care system, insisted Geron Corp. CEO Thomas Okarma. (BioWorld Today)
Step ahead of the game with the Biotech Superbook!
They say you can't know where you're going, if you don't know where you've been... BioWorld Biotech Super Book — coverage like never before! We've taken one of our most requested resources — The BioWorld State of the Industry Report — and enhanced it! The brand new 475-page report includes the deals, the projections, the R&D, the latest trends, the industry analysis, and the top drugs that surrounded our year... and shaped the future. From the bench to Wall Street to DC to Europe — The BioWorld Biotech SuperBook brings you the defining moments from the year and shows you the future from all angles. You can't afford to be without it!
Is Venture Riding the Summer Roller Coaster?
Throughout July, the Dow jerked everyone around as it whipped up and down by 100+ points on what felt like a daily basis. It's become a regular aerobic activity trying to follow the bouncing portfolio valuation. (BioWorld Perspectives)
Cerenis' Series C Adds €40M for HDL Mimetic in CV Disease
Five-year-old French biotech Cerenis Therapeutics SA pulled in its third major venture round, adding €40 million (US$51.9 million) in Series C funding to advance its lead program, HDL-mimetic CER-001, into Phase II testing in cardiovascular disease. (BioWorld International)
